Literature DB >> 19184427

The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea.

Nayoung Kim1, Sung-Il Cho, Hye Seung Lee, Ji Hyun Park, Jee Hyun Kim, Joo Sung Kim, Hyun Chae Jung, In Sung Song.   

Abstract

The p53 gene has been referred to as 'the guardian of the genome' because it controls apoptosis and cell cycle arrest. The purpose of this study was to evaluate the association of p53 codon 72 genetic polymorphism and the p53 immunohistochemistry with Helicobacter pylori-associated gastroduodenal diseases, including gastric cancer. This study included 1,852 subjects: controls and patients with gastric cancer, dysplasia, benign gastric ulcers, and duodenal ulcers (DU). Biallelic polymorphism was genotyped by restriction fragment length polymorphism. Immunohistochemical analysis for the detection of mutant type p53 expression was performed. The frequency of the Pro/Pro allele of the p53 codon 72 was higher in the patients with H. pylori-positive dysplasia than in controls (OR: 2.3, 95% CI: 1.3-4.3), but it was less frequent among patients with a H. pylori-positive DU (OR: 0.5, 95% CI: 0.3-0.8). However, there was no significant association with gastric cancer, including the location, stage, or histological type of gastric cancer. Expression of a mutant type of p53 protein was detected in 6.3% of dysplastic tissues and 26.5% of cancerous tissues compared 0% in the controls. Positive expression was higher in the intestinal type of cancer (34.9%) than in the diffuse type (15.0%; P = 0.001). These results suggest that genetic polymorphism of p53 codon 72 played a role in the determination of H. pylori-associated gastroduodenal diseases, but p53 immunostaining did not correlate with those of the p53 genetic polymorphism analysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184427     DOI: 10.1007/s10620-008-0688-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  60 in total

1.  p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.

Authors:  Y S Bian; M C Osterheld; F T Bosman; J Benhattar; C Fontolliet
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

2.  p53 polymorphism and risk of cervical cancer.

Authors:  A Hildesheim; M Schiffman; L A Brinton; J F Fraumeni; R Herrero; M C Bratti; P Schwartz; R Mortel; W Barnes; M Greenberg; L McGowan; D R Scott; M Martin; J E Herrera; M Carrington
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

3.  Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis.

Authors:  S J Hessey; J Spencer; J I Wyatt; G Sobala; B J Rathbone; A T Axon; M F Dixon
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

4.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

5.  p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.

Authors:  Marek Skacel; Robert E Petras; Lisa A Rybicki; Terry L Gramlich; Joel E Richter; Gary W Falk; John R Goldblum
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

6.  A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism.

Authors:  Zun-Wu Zhang; Paul Newcomb; Andrew Hollowood; Jyoti Gupta; Roger Feakins; Alan Storey; Michael J G Farthing; Derek Alderson; Jeff Holly
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

7.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  p53 polymorphisms and haplotypes in breast cancer.

Authors:  A Själander; R Birgander; G Hallmans; S Cajander; P Lenner; L Athlin; G Beckman; L Beckman
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

9.  Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa.

Authors:  M J Brito; G T Williams; H Thompson; M I Filipe
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

10.  The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas.

Authors:  S Andersson; E Rylander; A Strand; J Sällström; E Wilander
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

View more
  2 in total

1.  An updated meta-analysis of the p53 codon 72 polymorphism and gastric cancer risk.

Authors:  Kui-Jie Liu; Hai-Zhi Qi; Hong-Liang Yao; San-Lin Lei; Zhen-Dong Lei; Tie-Gang Li; Hua Zhao
Journal:  Mol Biol Rep       Date:  2012-06-16       Impact factor: 2.316

Review 2.  Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.

Authors:  Danilo do Rosário Pinheiro; Wallax Augusto Silva Ferreira; Mariceli Baia Leão Barros; Mariana Diniz Araújo; Symara Rodrigues-Antunes; Bárbara do Nascimento Borges
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.